Savant Capital LLC Invests $272,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Savant Capital LLC purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 2,208 shares of the specialty pharmaceutical company’s stock, valued at approximately $272,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. UMB Bank n.a. raised its stake in Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares during the period. Itau Unibanco Holding S.A. raised its stake in Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after buying an additional 172 shares during the period. GAMMA Investing LLC raised its stake in Jazz Pharmaceuticals by 49.8% during the 4th quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 206 shares during the period. Venturi Wealth Management LLC raised its stake in Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares during the period. Finally, Versant Capital Management Inc raised its stake in Jazz Pharmaceuticals by 56.7% during the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 350 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 5,053 shares of company stock worth $617,442. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Trading Up 1.1 %

Jazz Pharmaceuticals stock opened at $135.39 on Wednesday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $138.27. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market capitalization of $8.19 billion, a P/E ratio of 19.07, a PEG ratio of 0.92 and a beta of 0.56. The stock has a 50-day simple moving average of $123.73 and a 200 day simple moving average of $117.41.

Analyst Ratings Changes

JAZZ has been the topic of several research analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Needham & Company LLC reissued a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $180.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.